

## REMARKS

The Examiner's suggestion of amending the claims to recite a determination of LDL values and administering the active compounds to patients having an LDL value of less than 109 mg/dl has been adopted in claims 1 and 37. Support for this amendment is found at paragraph 2 line 6 of the specification and in original claim 2 which has now been canceled.


The 35 USC 102(b) rejection is respectfully traversed. Nothing in Davis suggests that galantamine should be administered to patients who have been determined to have low LDL-cholesterol or that a determination of LDL-cholesterol values should be a step to be taken before administering galanthamine to a patient. This disclosure therefore clearly does not anticipate the invention as now claimed.

Turning to the 35 USC 103 rejection, the articles by Kivipelto and Simons teach away from the present invention. Galanthamine is known for the treatment of Alzheimer's disease. Kivipolto teaches that there is some correlation between elevated cholesterol values (no distinction was made between totla cholesteroal and low LDL\_cholesterol) and Alzheimer's disease. Based on this teaching there would be no motivation to administer an Alzheimer's drug to patients with low cholesterol values. Similar comments apply with respect to the Simons article. Simons reports that studies indicate that lowering of cholesterol reduces the incidence of Alzheimer's disease. Based on thios again there would be no reason to administer an Alzheimer's drug to patients having low LDL-cholesterol.

It is submitted therefore that the art in no way teaches the treatment of cognitive dysfunction with galanthamine or any nicotinic allosteric potentiator, an acetylcholinesterase inhibitor, nicotine, a nicotinic agonist or a mixture thereof and that the claims submitted should be allowed and the withdrawn claims recombined.

In view of the foregoing, it is submitted that this application is now in order for allowance and an early action to this end is respectfully solicited.

Respectfully submitted,

  
John Richards  
LADAS & PARRY  
26 West 61st. Street  
New York, New York 10023  
Reg. 31053  
Tel. (212) 708-1915